2026 Q2 - tulosraportti
45 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 393 | - | - | ||
| 436 | - | - | ||
| 846 | - | - | ||
| 139 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·9 t sitten · MuokattuCompany presentation Q4 2026 https://www.circio.com/en/wp-content/uploads/sites/2/2023/10/circio-pitchdeck-norsk.pdf
·11 t sitten🧬 BIG PHARMA DOES NOT CARE THAT THE RNA IS ROUND. THEY CARE ABOUT THIS: More protein. Less vector. Longer effect. That is essentially the entire Circio case distilled. The problem with current AAV? Linear mRNA disappears quickly. The solution has been to compensate with more vector. Higher dose = more toxicity, more immune response, more expensive manufacturing. circVec attacks the problem from the opposite side: Do not push more vector. Get more out of each vector. And preclinically they are already seeing: → higher protein output per vector → longer expression → early signals of less liver off-targeting / cellular stress This is the point many still miss. Circio is not selling "circular RNA". They are trying to solve one of the most expensive bottlenecks in gene therapy: DOSE. If circVec can deliver the same or better therapeutic effect with substantially less vector— then this suddenly becomes about safety, durability AND economics at the same time. Big Pharma does not buy circles. They buy solutions to expensive problems. 🧬♟️ We know what we own. 🧱♟️🍷
- ·11 t sittenShare price change since September 21 at 16: 0 %
When I started in this it was stable around 90 øre. This summer it was stable around 7 kr. Now in October stable around 11 kr. So if they continue to deliver I think it can easily become stable quite a bit higher. Absolutely top this 👍 we who have been patient have been well paid and think we can easily get much more. This summer at least many were going to wait until it reached 5-6 kr I remember, they are still waiting - ·11 t sitten · Muokattu27.–30. October: ESGCT Hamburg – Circio is presenting three times. Wiklund has confirmed that the next significant research update is "just around the corner". New strong circVec/in vivo CAR-T data could significantly lift the technology's value. Three presentations provide an exciting arena to highlight the potential. Disease model data is expected in H2 2026, but Circio has not confirmed an exact date. Positive in vivo CAR-T or CNS/heart/eye data could become a significant catalyst. Most exciting time in Circio's lifetime.
·11 t sittenHave many here heard the podcast that Hulten shared? Thoughts? Personally I think this takes time, am of course at least as optimistic as I have been since 0.58 ore and have ironclad faith in the long term I get an impression that there won't be shared such extreme news this year but, the start of 27 is what I am left with after hearing this
Isn't Thomas saying that they now HAVE shown +200x in heart with 5.0? And that he looks forward to seeing if it is the same in CNS/EYE? I believe that earlier in September only "potential +200x" was stated. 💰🤩
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
45 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sitten · MuokattuCompany presentation Q4 2026 https://www.circio.com/en/wp-content/uploads/sites/2/2023/10/circio-pitchdeck-norsk.pdf
- ·11 t sitten🧬 BIG PHARMA DOES NOT CARE THAT THE RNA IS ROUND. THEY CARE ABOUT THIS: More protein. Less vector. Longer effect. That is essentially the entire Circio case distilled. The problem with current AAV? Linear mRNA disappears quickly. The solution has been to compensate with more vector. Higher dose = more toxicity, more immune response, more expensive manufacturing. circVec attacks the problem from the opposite side: Do not push more vector. Get more out of each vector. And preclinically they are already seeing: → higher protein output per vector → longer expression → early signals of less liver off-targeting / cellular stress This is the point many still miss. Circio is not selling "circular RNA". They are trying to solve one of the most expensive bottlenecks in gene therapy: DOSE. If circVec can deliver the same or better therapeutic effect with substantially less vector— then this suddenly becomes about safety, durability AND economics at the same time. Big Pharma does not buy circles. They buy solutions to expensive problems. 🧬♟️ We know what we own. 🧱♟️🍷
- ·11 t sittenShare price change since September 21 at 16: 0 %When I started in this it was stable around 90 øre. This summer it was stable around 7 kr. Now in October stable around 11 kr. So if they continue to deliver I think it can easily become stable quite a bit higher. Absolutely top this 👍 we who have been patient have been well paid and think we can easily get much more. This summer at least many were going to wait until it reached 5-6 kr I remember, they are still waiting
- ·11 t sitten · Muokattu27.–30. October: ESGCT Hamburg – Circio is presenting three times. Wiklund has confirmed that the next significant research update is "just around the corner". New strong circVec/in vivo CAR-T data could significantly lift the technology's value. Three presentations provide an exciting arena to highlight the potential. Disease model data is expected in H2 2026, but Circio has not confirmed an exact date. Positive in vivo CAR-T or CNS/heart/eye data could become a significant catalyst. Most exciting time in Circio's lifetime.
- ·11 t sittenHave many here heard the podcast that Hulten shared? Thoughts? Personally I think this takes time, am of course at least as optimistic as I have been since 0.58 ore and have ironclad faith in the long term I get an impression that there won't be shared such extreme news this year but, the start of 27 is what I am left with after hearing thisIsn't Thomas saying that they now HAVE shown +200x in heart with 5.0? And that he looks forward to seeing if it is the same in CNS/EYE? I believe that earlier in September only "potential +200x" was stated. 💰🤩
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 393 | - | - | ||
| 436 | - | - | ||
| 846 | - | - | ||
| 139 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
45 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sitten · MuokattuCompany presentation Q4 2026 https://www.circio.com/en/wp-content/uploads/sites/2/2023/10/circio-pitchdeck-norsk.pdf
- ·11 t sitten🧬 BIG PHARMA DOES NOT CARE THAT THE RNA IS ROUND. THEY CARE ABOUT THIS: More protein. Less vector. Longer effect. That is essentially the entire Circio case distilled. The problem with current AAV? Linear mRNA disappears quickly. The solution has been to compensate with more vector. Higher dose = more toxicity, more immune response, more expensive manufacturing. circVec attacks the problem from the opposite side: Do not push more vector. Get more out of each vector. And preclinically they are already seeing: → higher protein output per vector → longer expression → early signals of less liver off-targeting / cellular stress This is the point many still miss. Circio is not selling "circular RNA". They are trying to solve one of the most expensive bottlenecks in gene therapy: DOSE. If circVec can deliver the same or better therapeutic effect with substantially less vector— then this suddenly becomes about safety, durability AND economics at the same time. Big Pharma does not buy circles. They buy solutions to expensive problems. 🧬♟️ We know what we own. 🧱♟️🍷
- ·11 t sittenShare price change since September 21 at 16: 0 %When I started in this it was stable around 90 øre. This summer it was stable around 7 kr. Now in October stable around 11 kr. So if they continue to deliver I think it can easily become stable quite a bit higher. Absolutely top this 👍 we who have been patient have been well paid and think we can easily get much more. This summer at least many were going to wait until it reached 5-6 kr I remember, they are still waiting
- ·11 t sitten · Muokattu27.–30. October: ESGCT Hamburg – Circio is presenting three times. Wiklund has confirmed that the next significant research update is "just around the corner". New strong circVec/in vivo CAR-T data could significantly lift the technology's value. Three presentations provide an exciting arena to highlight the potential. Disease model data is expected in H2 2026, but Circio has not confirmed an exact date. Positive in vivo CAR-T or CNS/heart/eye data could become a significant catalyst. Most exciting time in Circio's lifetime.
- ·11 t sittenHave many here heard the podcast that Hulten shared? Thoughts? Personally I think this takes time, am of course at least as optimistic as I have been since 0.58 ore and have ironclad faith in the long term I get an impression that there won't be shared such extreme news this year but, the start of 27 is what I am left with after hearing thisIsn't Thomas saying that they now HAVE shown +200x in heart with 5.0? And that he looks forward to seeing if it is the same in CNS/EYE? I believe that earlier in September only "potential +200x" was stated. 💰🤩
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 393 | - | - | ||
| 436 | - | - | ||
| 846 | - | - | ||
| 139 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt